Uncategorized

OWC jumps 27% on news it will discuss myeloma drug at MJBizCon

By November 9, 2018 No Comments

Tel Aviv-based OWC Pharma, a developer of cannabinoid-based therapies for various disorders, recently announced successful tests in October of its new delivery formulation for Multiple Myeloma therapy. This week, when it announced it will attend the 2018 MJBizCon (Marijuana Business Conference) in Las Vegas, on November 14-16, 2018, its stock price jumped 25% in two days.

Multiple Myeloma is an incurable blood cancer that effects 30,000 new patients a year in the USA alone. Cannabis-based therapies could be a new frontier in fighting the disease. According to OWC CEO Dr. Stanley Hirsch, “this potentially moves cannabis from being a cancer palliative to becoming a cancer therapeutic.”

MJBizCon, is a conference that aims to drive cannabis business deals. There will be 20,000+ cannabis professionals and 1,000+ exhibitors at the event. OWC will hold meetings with investors, researchers and business partners there.

In the recent tests of its new delivery formulation for Multiple Myeloma therapy, OWC administered OWC-1808 in vivo into animals and it was found to be safe and tolerable. The formulation will allow delivery of high doses of CBD and THC with good bioavailability.

To schedule a meeting or learn more about OWC research, contact Ms. Miri Chen at miri.chen@owcpharma.com

OWC, through its Israeli subsidiary, One World Cannabis Ltd., conducts research to develop cannabis-based treatments for multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. It is s also developing delivery systems of medical cannabis. All OWC research is conducted at Israeli hospitals and scientific institutions.

Sources

OWC website

OWC press release

OWC press release

Leave a Reply